

## **GPP2 Steering Committee**

Wendy P Battisti, Associate Director, Scientific and Medical Publications, Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA

Dan Bridges, Group Program Director, Excerpta Medica, Elsevier, London, UK

Victoria Bruce-Winkler, Medical Publications Consultant, Dunblane, UK

Joanne M Conaty, Senior Director, Clinical Strategy and Planning, AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

John Draper, Senior Vice President, Peloton Advantage, Parsippany, NJ, USA

John M Ellison, Senior Manager, Scientific Publications, LifeScan, Inc., Milpitas, CA, USA

Elizabeth A Field, President, Field Advantage Medical Communications, Chapel Hill, NC, USA

Chris Graf, Associate Editorial Director, John Wiley & Sons, Wiley-Blackwell, Oxford, UK

James A Gurr, Director, Publication Planning and Development, Pfizer Inc., Collegeville, PA, USA

Mary-Ellen Marx, Senior Manager, Medical Education, PharmaWrite, part of Jobson Healthcare Information, LLC, Princeton, NJ, USA

Jane Moore, Publications Specialist, Medtronic, Inc., Minneapolis, MN, USA

Mina Patel, Senior Director, Medical Communications, Cephalon, Inc., Frazer, PA, USA

Carol Sanes-Miller, Global Publications Manager, Scientific Communications, AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

Yvonne E Yarker, Senior Vice President, Medical Communications, Scientific Connexions, *a division of KnowledgePoint360*, Newtown, PA, USA

## **Contributions**

The opinions expressed in GPP2 do not necessarily represent those of the contributors' employers.

JM and JD were members of the steering committee and contributed to discussions about the recommendations made in this document (JD in particular on managed care, pharmaco-economic, and health outcomes). CG wrote the first and final draft; WPB wrote the draft sections on publication planning, documentation, and conflict of interest; DB, EAF, CSM, and MP contributed to outline, intermediate drafts, and revisions; VBW wrote the draft sections on authors, contributorship, acknowledgements, and medical writers; JMC the draft duplicate publication section, JME the draft review articles section, JAG the draft publication steering committee section, and YEY the draft access to data section. MEM compiled steering committee comments after the consultation, and contributed to outline, intermediate drafts, and revisions. All the authors contributed to the literature analysis and review before writing these guidelines. All the authors contributed to the outline and to the first and subsequent drafts, to interpretation of the comments

gathered during the consultation phase, and reviewed the final draft. All the authors approved GPP2 and CG is the guarantor.

## **Disclosures**

All the contributors are members of the International Society for Medical Publication Professionals, a not-for-profit organisation with membership comprising pharmaceutical, biotechnology, and device industries; medical communications agencies; publishers; and independent medical writers. The society is funded by its membership. WPB and JME have stock in Johnson & Johnson; VBW has stock in Novo Nordisk and Parexel; JMC has stock in AstraZeneca; JAG has stock in Wyeth; and MP has stock in Cephalon. CG is a council member of COPE (Committee on Publication Ethics). JAG was an employee of Wyeth, which was acquired by Pfizer in October, 2009. VBW has previously been employed by Novo Nordisk to work with publications.

## **Funding**

The International Society for Medical Publication Professionals provided the contributors with meeting and teleconferencing facilities and web conferencing technology.

## **Acknowledgements**

International Society for Medical Publication Professionals initiated the development of GPP2. The contributors thank the consultation panel for their comments. We thank Elizabeth Wager, Sideview, for her work on the guidelines that GPP2 updates (some of the earlier guidance remains in the new guidelines) and for her willingness for International Society for Medical Publication Professionals to sponsor GPP2. We thank Sheema Sheikh at Excerpta Medica, Elsevier for compiling comments from the consultation.